Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 655

Similar articles for PubMed (Select 12117958)

1.

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.

Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, Blackman MJ, Thomas AW.

Infect Immun. 2002 Aug;70(8):4471-6. Erratum in: Infect Immun 2002 Oct;70(10):5901.

2.

The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines.

Spiegel H, Boes A, Kastilan R, Kapelski S, Edgue G, Beiss V, Chubodova I, Scheuermayer M, Pradel G, Schillberg S, Reimann A, Fischer R.

Biotechnol J. 2015 Apr 24. doi: 10.1002/biot.201500055. [Epub ahead of print]

PMID:
25913888
3.

Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria.

Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, Cheng YS, Stubbs J, Tetteh KK, Conway DJ, McCarthy JS, Muller I, Marsh K, Anders RF, Beeson JG.

Immunity. 2015 Mar 17;42(3):580-90. doi: 10.1016/j.immuni.2015.02.012.

4.

PfRH5 as a candidate vaccine for Plasmodium falciparum malaria.

Drew DR, Beeson JG.

Trends Parasitol. 2015 Mar;31(3):87-8. doi: 10.1016/j.pt.2015.02.001. Epub 2015 Feb 19.

PMID:
25704640
5.

PfRON3 is an erythrocyte-binding protein and a potential blood-stage vaccine candidate antigen.

Zhao X, Chang Z, Tu Z, Yu S, Wei X, Zhou J, Lu H, Jiang N, Chen Q.

Malar J. 2014 Dec 12;13:490. doi: 10.1186/1475-2875-13-490.

6.

Expanding the toolbox in pursuit of a strain transcendent malaria vaccine.

Frosch AE, John CC.

Am J Trop Med Hyg. 2015 Jan;92(1):1-2. doi: 10.4269/ajtmh.14-0662. Epub 2014 Nov 24. No abstract available.

PMID:
25422397
7.

Genome-level determination of Plasmodium falciparum blood-stage targets of malarial clinical immunity in the Peruvian Amazon.

Torres KJ, Castrillon CE, Moss EL, Saito M, Tenorio R, Molina DM, Davies H, Neafsey DE, Felgner P, Vinetz JM, Gamboa D.

J Infect Dis. 2015 Apr 15;211(8):1342-51. doi: 10.1093/infdis/jiu614. Epub 2014 Nov 7.

PMID:
25381370
8.

Innate sensing of malaria parasites.

Gazzinelli RT, Kalantari P, Fitzgerald KA, Golenbock DT.

Nat Rev Immunol. 2014 Nov;14(11):744-57. doi: 10.1038/nri3742. Epub 2014 Oct 17. Review.

PMID:
25324127
9.

Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits.

Boes A, Spiegel H, Edgue G, Kapelski S, Scheuermayer M, Fendel R, Remarque E, Altmann F, Maresch D, Reimann A, Pradel G, Schillberg S, Fischer R.

Plant Biotechnol J. 2015 Feb;13(2):222-34. doi: 10.1111/pbi.12255. Epub 2014 Sep 18.

PMID:
25236489
10.

Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Harris KS, Adda CG, Khore M, Drew DR, Valentini-Gatt A, Fowkes FJ, Beeson JG, Dutta S, Anders RF, Foley M.

Infect Immun. 2014 Nov;82(11):4707-17. doi: 10.1128/IAI.02061-14. Epub 2014 Aug 25.

11.

A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein.

Ord RL, Caldeira JC, Rodriguez M, Noe A, Chackerian B, Peabody DS, Gutierrez G, Lobo CA.

Malar J. 2014 Aug 18;13:326. doi: 10.1186/1475-2875-13-326.

12.

Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies.

Wright KE, Hjerrild KA, Bartlett J, Douglas AD, Jin J, Brown RE, Illingworth JJ, Ashfield R, Clemmensen SB, de Jongh WA, Draper SJ, Higgins MK.

Nature. 2014 Nov 20;515(7527):427-30. doi: 10.1038/nature13715. Epub 2014 Aug 17.

13.

Protecting capacity against malaria of chemically defined tetramer forms based on the Plasmodium falciparum apical sushi protein as potential vaccine components.

Vanegas M, Bermúdez A, Guerrero YA, Cortes-Vecino JA, Curtidor H, Patarroyo ME, Lozano JM.

Biochem Biophys Res Commun. 2014 Aug 15;451(1):15-23. doi: 10.1016/j.bbrc.2014.06.143. Epub 2014 Jul 22.

PMID:
25063026
14.

Plasmodium falciparum double C2 domain protein, PfDOC2, binds to calcium when associated with membranes.

Jean S, Zapata-Jenks MA, Farley JM, Tracy E, Mayer DC.

Exp Parasitol. 2014 Sep;144:91-5. doi: 10.1016/j.exppara.2014.06.015. Epub 2014 Jun 30.

PMID:
24992295
15.

Effect of choline kinase inhibitor hexadecyltrimethylammonium bromide on Plasmodium falciparum gene expression.

Razak MR, Abdullah NR, Chomel R, Muhamad R, Ismail Z.

Southeast Asian J Trop Med Public Health. 2014 Mar;45(2):259-66.

PMID:
24968665
16.

Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria.

Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, Long CA, Narum DL, Miller LH.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10311-6. doi: 10.1073/pnas.1409928111. Epub 2014 Jun 23.

17.

Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection.

Raj DK, Nixon CP, Nixon CE, Dvorin JD, DiPetrillo CG, Pond-Tor S, Wu HW, Jolly G, Pischel L, Lu A, Michelow IC, Cheng L, Conteh S, McDonald EA, Absalon S, Holte SE, Friedman JF, Fried M, Duffy PE, Kurtis JD.

Science. 2014 May 23;344(6186):871-7. doi: 10.1126/science.1254417.

18.

Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Gupta PK, Mukherjee P, Dhawan S, Pandey AK, Mazumdar S, Gaur D, Jain SK, Chauhan VS.

Clin Vaccine Immunol. 2014 Jun;21(6):886-97. doi: 10.1128/CVI.00179-14. Epub 2014 Apr 30.

19.

Synthetic peptides derived from the C-terminal 6kDa region of Plasmodium falciparum SERA5 inhibit the enzyme activity and malaria parasite development.

Kanodia S, Kumar G, Rizzi L, Pedretti A, Hodder AN, Romeo S, Malhotra P.

Biochim Biophys Acta. 2014 Sep;1840(9):2765-75. doi: 10.1016/j.bbagen.2014.04.013. Epub 2014 Apr 25.

PMID:
24769454
20.

Vaccines against tropical parasitic diseases: a persisting answer to a persisting problem.

Sacks DL.

Nat Immunol. 2014 May;15(5):403-5. doi: 10.1038/ni.2853. No abstract available.

PMID:
24747701
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk